FDA just issued a warning to healthcare professionals that Lunesta can cause lingering effects resulting in next-day impairment. The FDA has recommended that doctors advise patients to decrease their starting dose of Lunesta to 1 mg at bedtime. Both women and men have been reported to be equally effected. The previous recommended dosage of Lunesta was 3 mg which was found to possibly effect a patients driving skills, memory, and coordination up to eleven hours after taking a nightly dose.
To read the entire article from Drugs.com click here: http://www.drugs.com/fda/eszopiclone-containing-sleep-aids-safety-communication-can-cause-next-day-impairment-13545.html?utm_source=ddc&utm_medium=email&utm_campaign=FDA+Alert+-+Drug+Safety+Communication%3A+Eszopiclone+Containing+Sleep+Aids+-+Can+Cause+Next-Day+Impairment
To read the FDA’s Safety Announcement click here: http://www.fda.gov/Drugs/DrugSafety/ucm397260.htm
Nathan T. Williams, Attorney at Law